Anas Younes on AstraZeneca’s Aims in Blood Cancer to Be Presented at ASH25
Anas Younes, SVP, CMO and Global Head of Hematology, Oncology R and D at AstraZeneca, shared on LinkedIn:
”Every year, ASH25 is a moment to recognize the progress we’re making in hematology and celebrate the breakthroughs that help to transform care, from next-generation T-cell engagers to advances in cell therapy.
At AstraZeneca, we’re advancing a diverse range of innovations and expanding access to next-generation therapies that aim to deliver deeper, more durable responses while easing the daily burden of treatment for people living with blood cancer.
It’s great to continue these conversations throughout ASH and explore how these breakthroughs are potentially shaping a more hopeful future for blood cancer care.
Read my latest article to learn more.”
All from ASH25 featured in Hemostasis Today.
-
Mar 10, 2026, 14:33Eugene Tang: A Look at What’s Happening in Life After Stroke Research Across Europe at ELASF 2026
-
Mar 10, 2026, 14:25Ahd Elmahi: Complex Case of Catecholamine-Induced Multiorgan Failure and Arterial Thrombosis in Community-Acquired Pneumonia
-
Mar 10, 2026, 13:36Nirupama Yechoor: How Survivors of Stroke Define Spiritual Wellbeing in Recovery
-
Mar 10, 2026, 13:17Jeannie Devereaux: A Novel Technique for Precise High-Dose PRP Injection in Hip Labral Tear
-
Mar 10, 2026, 13:13Wolfgang Miesbach: Highlighting a Critical and Overlooked Dimension of Rare Bleeding Disorders in Women at EAHAD 2026
-
Mar 10, 2026, 13:08Michael Ertl: Honoured To Be Elected Fellow of the European Stroke Organisation
-
Mar 10, 2026, 13:00Nita Radhakrishnan: Benchmarking Hemophilia Care Across Global Income Settings Using Data from India
-
Mar 10, 2026, 12:59Hisam Siddiqi: Night Sweats Are Not Always a Hematological Plot Twist
-
Mar 10, 2026, 12:54Tzu-Fei Wang: Reassuring Real-World Data for Clinicians to Guide Anticoagulation in Prostate Cancer